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ABSTRACT
OBJECTIVE: To assess the prevalence and factors associated with the use of the expanded 
Brazilian People’s Pharmacy Program among older adults and the reasons for not using it. 
METHODS: In this population-based cross-sectional study conducted in the urban area of 
Pelotas, RS, Southern Brazil, we evaluated 1,305 older adults (aged 60 years or over) who had used 
medication in the last 15 days. Independent variables were socioeconomic factors, economic 
status, household income in minimum wages, educational attainment in years of schooling and 
occupational status. Demographic variables were sex, age, marital status, and self-reported skin 
color/race. Poisson regression was employed to analyze the factors associated with the use of 
the program.
RESULTS: The prevalence of use was 57.0% whilst the prevalence of knowledge of the program 
was 87.0%. In individuals aged 80 years or over, use of the program was 41.0%. As to the origin 
of the prescriptions used by older adults, 46.0% were from the Brazilian Unified Health System. 
The main reasons for not using the program were: difficulty in getting prescriptions, medication 
shortage, and ignorance about the medications offered and about the program. Higher age, lower 
income, presence of chronic diseases, and use of four or more medications were associated with 
use of the program. 
CONCLUSIONS: It is necessary to expand the knowledge and use of the Brazilian People’s 
Pharmacy Program, especially among older adults, and to improve the dissemination of its list 
of medications to users and physicians. Thus it will be possible to reduce spending on long-term 
medications, which are especially important for this population.
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INTRODUCTION
Ensuring access to basic and essential medications to all individuals is a priority in today’s 
health policies13,a. The Federal Government launched in 2004 the Programa Farmácia Popular 
do Brasil (PFPB – Brazilian People’s Pharmacy Program) as part of the Brazilian Unified Health 
System (SUS)b,c,d. This strategy aims to promote the expansion of access to medication and 
equal serviceb to the entire population. The purpose is to avoid treatment quitting, especially 
by individuals with low income who use private health services, but have difficulty in buying 
the required medications in regular drugstores20,e.
The PFPB develops two axes of action: its own network of people’s pharmacies and the 
Aqui tem Farmácia Popular (People’s Pharmacy Here) extended network (PFPB-E). People’s 
Pharmacies, in operation since 2004, dispense 112 medications at cost value, representing 
a reduction of up to 90.0% of the market value. The PFPB-E, considered an expansion of the 
PFPB in partnership with private pharmacies and drugstores, was created with the goal of 
broadening the coverage of pharmaceutical assistance, promoting the integrality of health 
care5. In this mode, the Ministry of Health (MS) subsidizes 90.0% of the reference value for 
medication for diseases such as dyslipidemia, Parkinson’s disease, glaucoma, osteoporosis 
and rhinitis, in addition to birth control and adult diapersf. In 2011, with the creation of the 
Saúde Não Tem Preço (Health is Priceless) program, the two axes of action began dispensing 
free medication for asthma, diabetes and hypertensiong.
Although the program is directed to all age groups, it is especially important for older 
adults, who tend to have bigger health needs, resulting in increased use of health services 
and medications5,19,h. In this sense, the PFPB-E helps control and prevent chronic diseases, 
increasing the population’s access to medical therapy and reducing the impact of medication 
cost on family budgets3.
As the PFPB is relatively new, studies about it are scarce and give greater emphasis to its own 
network, which was consolidated first. They are restricted to describing the program in terms 
of medication availability compared with the public and private sectors and the profile of 
the population that uses the program8,14,15. Although this study addresses the PFPB only on 
the private network, since there are no program units in the city of Pelotas, this is the first 
population-based study to obtain information on the use of the PFPB-E for each medicationi,j.
Considering the importance of the universalization of access to medications for 
population health and the role of the PFPB to expand access, we aimed to assess the 
prevalence and factors associated with the use of the PFPB-E among older adults and 
the reasons for not using it. 
METHODS
This population-based cross-sectional study was performed with older adults (aged 60 years 
or over) in the urban area of Pelotas, RS, Southern Brazil. There are approximately 46,099 
older adults in the urban area of this city (2010 Demographic Census, IBGE)k. According to 
data from the local health surveillance, there are about 165 pharmacies and drugstores in 
Pelotas, of which 62.0% are linked to the PFPB-E. This study is part of research “Avaliação da 
saúde de idosos da cidade de Pelotas”, conducted in the first semester of 2014.
The sample size estimation to study the prevalence of the use of the PFPB-E considered the 
following parameters: 95% confidence level, 60.0% estimated prevalence, tolerable error 
of four percentage points, and an increase of 10.0% for losses and refusals. To assess the 
factors associated with the outcome, the parameters used were: 95% confidence level, 80.0% 
minimum statistical power, 1:5 ratio between unexposed and exposed, 48.0% estimated 
prevalence for the unexposed, 1.3 prevalence ratio, an increase of 15.0% for confounding 
factors, and 1.5 design effect, totaling an estimated sample size of 1,246 older adults.
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Sample selection was performed in two stages. In the first, the 488 census districts of Pelotas 
were listed and sorted according to average income, with a random sampling of 133 districts. 
This strategy ensured the inclusion of several neighborhoods of different economic status. 
In the second stage, occupied households in the selected districts were counted, estimating 
about one older adult for every three households. We drew 31 households by district, with the 
aim of reducing design effects, and sampled approximately 10 households in each selected 
district, totaling 4,123 households. All people aged 60 years or over in each household were 
invited to participate in the study. We excluded those living in nursing homes, unable to answer 
the questionnaire for mental or physical issues, and who lacked a companion or caregiver.
The outcome “use of the PFPB” was defined as obtaining at least one medication from the 
PFPB among older adults who had used any medication in the last 15 days. “Knowledge 
of the PFPB” was checked by answering yes to the question “Do you know the People’s 
Pharmacy Program?”
When respondents reported not obtaining the medication from the PFPB-E or SUS 
pharmacies (municipal or primary health care units), they were asked if they had tried to. In 
case of an affirmative answer, they were asked the reasons for failing to get the medication 
and, in case of a negative answer, why they had not sought the PFPB-E. The packaging or 
prescription of every medication used was requested to verify the correct names and later 
classify them by pharmacological groups. To trace the origin of prescriptions, the following 
question was made: “Who prescribed this medication for you?” (SUS physician or dentist; 
private or health plan physician or dentist).
The independent variables were: socioeconomic factors; economic status, classified according 
to the Brazilian Association of Market Research Companies (ABEP)l (Social Classes A or 
B; C; D or E), categorized household income in minimum wages (≤ 1; 2-3; 4-5; 6-9; ≥ 10), 
educational attainment in years of schooling (none; up to three years; four to seven years, 
eight to 10 years; 11 or more) and occupational status (working; retired or receiving the 
social security disability insurance; retired and working; homemaker or unemployed). 
Demographic variables were sex (male; female), age in years according to four categories 
(60-64; 65-69; 70;-79; ≥ 80), marital status (with a partner; without a partner) and self-reported 
skin color/race (white; nonwhite). 
To describe the sample according to morbidities, the medical diagnosis reported by the 
respondent was characterized as: diabetes, hypertension, respiratory diseases (asthma; 
bronchitis; emphysema), rhinitis, glaucoma, Parkinson’s disease, dyslipidemia, and 
osteoporosis. The need for using long-term medication was assessed by the question “Do you 
need to take any long-term medication? Consider long-term medication as those you use 
regularly without a date to stop”. The number of medications used by the older adult in the 
last 15 days (1, 2, 3, and ≥ 4) was also assessed. Social support was considered present if 
older adults had someone to help with their needs.
Thirteen trained interviewers visited the selected households to deliver a study presentation 
letter explaining it and inviting older adults to participate. After eligible individuals’ 
acceptance, interviews were scheduled according to their availability. Electronic 
questionnaires with precoded questions were applied using netbooks.
We considered as losses and refusals the interviews not conducted after three attempts, one 
of those by a study supervisor. Quality control was performed by the field supervisor with 
10.0% of respondents selected at random. We used a shorter version of the questionnaire, 
composed of 19 questions. Correlation was analyzed by the kappa index.
Analyses were performed in the Stata 12.1 program. The sample was described in relation 
to the independent variables, and the prevalence of the outcome “use of the PFPB-E” 
was estimated with the respective confidence intervals for individuals who had used any 
medication in the last 15 days. To estimate the prevalence of reasons for not using the 
program, we utilized a stratified analysis by age.
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Table 1. Description of the sample of older adults who had used medications in the last 15 days according to demographic and socioeconomic 
variables stratified by age. Pelotas, RS, Southern Brazil, 2014. (N = 1,305)
Variable na % 95%CI
60-79 years
95%CI
≥ 80 years 
95%CI
n % n %
Age
60-64 345 26.5 24.1–28.9 - - - - - -
65-69 321 24.7 22.3–27.0 - - - - - -
70-79 418 32.1 29.6–34.7 - - - - - -
≥ 80 217 16.7 14.6–18.7 - - - - - -
Sex
Male 459 35.2 32.6–37.8 388 35.8 32.9–38.6 70 32.3 25.9–38.5
Female 846 64.8 62.2–67.4 696 64.2 61.3–67.0 147 67.7 61.4–74.0
Marital status
Living without a partner 620 47.6 44.9–50.3 468 42.6 39.6–45.5 158 72.8 66.8–78.7
Living with a partner 682 52.4 49.7–55.1 624 57.4 54.4–60.3 59 27.2 21.2–33.1
Skin color/Race 
Nonwhite 205 15.8 13.8–17.7 167 15.2 13.1–17.3 40 18.4 13.2–23.6
White 1,097 84.2 82.3–86.2 925 84.8 82.6–86.9 177 81.6 76.3–86.7
Educational attainment (in years of schooling)
0 176 13.6 11.7–15.5 120 11 9.16–12.9 57 26.6 20.7–32.6
≤ 3 288 23.1 20.7–25.3 244 22.5 20.0–24.9 56 26.2 20.2–32.1
4-7 391 30.2 27.7–32.7 339 31.2 28.3–33.8 56 26.2 20.2–32.1
8-10 132 10.2 8.5–11.8 122 11.2 9.4–13.2 10 4.7 1.8–7.5
≥ 11 296 22.9 20.6–25.2 261 24.1 21.6–26.7 35 16.3 11.3–21.3
Occupational status 
Working 89 7.4 5.9–8.8 90 8.8 6.9–10.4 1 0.5 –0.05–1.5
Retired or receiving the social  
security disability insurance
871 72.0 69.5–74.6 705 69.2 66.3–72.0 169 87.1 82.3–91.8
Retired and working 125 10.3 8.6–12.1 117 11.2 9.4–13.3 10 5.2 2.0–8.2
Homemaker or unemployed 124 10.3 8.5–11.9 111 10.8 8.9–12.7 14 7.2 3.5–10.9
Economic classification - ABEP
A or B 449 36.4 33.7–39.1 373 36.3 33.3–39.2 76 36.7 30.0–43.3
C 639 51.8 49.0–54.6 544 52.9 49.8–55.9 98 47.3 40.5–54.2
D or E 145 11.8 9.9–13.5 111 10.8 8.9–12.7 33 16.0 10.9–21.0
Income in minimum wages 
≤ 1 125 10.3 8.6–12.0 105 10.4 8.4–12.2 19 9.4 5.3–13.5
2-3 519 42.7 39.8–45.4 445 43.7 40.6–46.7 77 38.3 31.5–45.1
4-5 257 21.1 18.8–23.4 207 20.3 17.8–22.8 51 25.4 19.3–31.4
6-9 177 14.5 12.6–16.5 142 13.9 11.9–16.2 35 17.4 12.1–22.7
≥ 10 139 11.4 9.6–13.2 119 11.7 9.6–13.6 19 9.5 5.3–13.5
Social supportb
No 96 7.4 6.0–8.8 84 7.8 6.2–9.4 11 5.1 6.1–9.4
Yes 1,205 92.6 91.2–94.0 997 92.2 90.6–93.8 205 94.9 90.6–93.8
Knowledge of the PFPB
No 165 12.6 10.8–14.5 101 9.3 7.6–11.0 62 28.7 22.6–34.8
Yes 1,139 87.4 85.5–89.1 984 90.7 88.9–92.4 154 71.3 65.2–77.4
Use of the PFPB-E 
No 534 43.2 40.4–45.9 408 39.8 36.8–42.8 123 58.8 52.1–65.6
Yes 703 56.8 54.1–59.6 616 60.2 57.2–63.2 86 41.2 34.4–47.9
Continue
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The factors associated with the use of PFPB-E were analyzed by Poisson regression, using 
the svy command to consider the study design effect. Variables with p > 0.2 not were taken 
to adjusted analysis. Regression followed a hierarchical model of backward elimination, 
which comprises three levels. The distal level included demographic and socioeconomic 
variables; the second level, the presence of morbidities; and the proximal level, knowledge 
of the PFPB and the number of medications used. Wald tests were used for heterogeneity 
and linear trend for the categorical variables. Variables with p < 0.2 were maintained in 
the model to control confounding factors. The significance level of 0.05 was considered.
To analyze the prevalence of PFPB-E use and associated factors, the total number of 
older adults who had used medication in the last 15 days was used as a denominator. 
To characterize medications (presence in the PFPB-E, classification by pharmacological 
group, gratuitousness of medications), total medications used were the denominator.
Table 1. Description of the sample of older adults who had used medications in the last 15 days according to demographic and socioeconomic 
variables stratified by age. Pelotas, RS, Southern Brazil, 2014. (N = 1,305). Continuation
Number of medications used
1 163 12.5 10.7–14.3 144 13.3 11.2–15.3 17 7.8 4.2–11.4
2 203 15.6 13.6–17.5 174 16.1 13.8–18.2 28 12.9 8.4–17.4
3 234 17.9 15.8–20.0 200 18.4 16.1–20.8 33 15.2 10.4–20.0
≥ 4 705 54.0 51.3–56.7 566 52.2 49.2–55.2 139 64.1 57.6–70.5
Need for long-term medication
No 68 5.2 4.0–6.4 60 5.5 4.2–6.9 8 3.7 1.1–6.2
Yes 1,237 94.8 93.6–96.0 1,024 94.5 93.1–95.8 209 96.3 93.8–98.8
Health conditions variables
Diabetes
No 973 74.6 72.3–76.9 802 73.9 71.4–76.6 169 77.9 72.3–83.4
Yes 331 25.4 23.0–27.7 282 26.1 23.4–28.6 48 22.1 16.6–27.7
Hypertension
No 371 28.5 26.0–30.9 309 28.7 26.0–31.5 61 28.2 22.2–34.3
Yes 933 71.5 69.1–74.0 766 71.3 68.5–73.9 155 71.7 65.7–77.8
Chronic respiratory diseases
No 1,077 82.7 80.7–84.8 905 83.6 81.4–85.8 169 77.9 72.3–83.4
Yes 225 17.3 15.2–19.3 177 16.4 14.2–18.6 48 22.1 16.5–27.6
Rhinitis
No 1,037 79.7 77.5–81.9 857 80.2 77.8–82.6 177 82.7 77.6–87.8
Yes 264 20.3 18.1–22.5 211 19.8 17.4–22.1 37 17.3 12.2–22.4
Glaucoma
No 1,201 92.3 90.9–93.8 1,010 93.3 91.9–94.8 188 88.3 83.9–92.6
Yes 100 7.7 6.2–9.1 72 6.7 5.2–8.1 25 11.7 7.3–16.1
Parkinson’s disease
No 1,280 98.3 97.6–99.0 1,068 98.7 98.0–99.4 209 96.3 93.8–98.9
Yes 22 1.7 0.9–2.3 14 1.3 0.06–1.9 8 3.7 1.1–6.2
Dyslipidemia
No 733 56.2 53.5–58.9 594 55.3 52.3–58.3 137 63.7 52.2–70.2
Yes 570 43.8 41.0–46.4 480 44.7 29.8–42.7 78 36.3 29.8–42.7
Osteoporosis
No 954 73.3 70.9–75.7 809 75.5 72.9–78.0 142 65.7 59.4–72.1
Yes 347 26.7 24.3–29.1 263 24.5 21.9–27.1 74 34.3 27.9–40.6
ABEP: Brazilian Association of Market Research Companies; PFPB: Brazilian People’s Pharmacy Program; PFPB-E: Brazilian People’s 
Pharmacy Program – expansion model 
a The maximum number of ignored values was 96, for occupational status.
b Social support: possibility of the older adult.
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This study was approved by the Research Ethics Committee of the Faculdade de Medicina 
of Universidade Federal de Pelotas (Opinion 472,357). All participants signed an informed 
consent form and were assured of the confidentiality of information given.
RESULTS
We interviewed 1,451 older adults. Losses and refusals totaled 21.3% (n = 393), most of them 
women and aged 60-69 years. Of the interviews, 4.0% were answered by a caregiver or companion. 
Most older adults (90.5%) had used at least one medication in the last 15 days. Among them, 
mean age was 70.9 years (SD = 8.2), 64.8% were women, 84.2% were white, 52.4% lived with a 
partner, and 30.2% had four to seven years of schooling. The predominant occupational status 
was retired or receiving the social security disability insurance (72.0%), 42.7% had a household 
income of two to three minimum wages, and 51.8% were part of social class C (Table 1).
About of 93.0% of the older adults reported having someone to help them with their needs. 
Regarding self-reported health conditions, 25.4% had diabetes, 71.5% hypertension, and 
17.3% respiratory diseases (Table 1).
The prevalence of PFPB-E use was 56.8% whilst the prevalence of knowledge of the program 
was 87.4%. About of 95.0% of the older adults had to take long-term medication, and 54.0% 
used four or more medications (Table 1). Of the individuals reporting long-term use of 
medication and taking medication in the last 15 days, 53.9% used the PFPB-E to obtain at 
least one medication (data not shown in tables). Considering age stratification, 71.3% of the 
people aged 80 years or over knew the PFPB, 41.2% had used the program and 64.1% used 
four or more medications (Table 1).
Table 2. Reasons for not using the Brazilian People’s Pharmacy Program, by older adults who had not obtained all their medications from 
the PFPB-E or SUS in the last 15 days, according to age. Pelotas, RS, Southern Brazil, 2014. (N = 1,014)
Variable
General
Age group
60-79 ≥ 80 
n % n % n %
Tried to obtain a medication from the PFPB-E
No 462 45.6 356 42.8 105 58.3
Yes 552 54.1 476 57.2 75 41.7
Reasons for trying and failing (n = 552) 
Difficulty in going to the pharmacy 31 5.7 20 4.2 9 12.3
Shortage of medication of the prescribed brand 49 8.9 41 8.7 8 10.8
Medication shortage 69 12.6 59 12.5 10 13.5
Difficulty in obtaining the prescription 93 17.0 77 16.3 16 21.6
Medication is not in the PFPB list 408 74.4 349 73.9 57 77.0
Other 43 7.8 38 8.0 5 6.8
Reasons for not trying (n = 469) 
Not trusting PFPB medication 15 3.4 13 3.8 2 2.0
A physician advised against it 16 3.6 13 3.8 3 3.0
Difficulty in going to the pharmacy 34 7.6 18 5.2 16 16.2
Difficulty in obtaining the prescription 55 12.3 43 12.5 12 11.9
Not knowing the PFPB 128 28.6 85 24.6 43 42.2
Not knowing which medications are available in the PFPB 174 39.1 127 36.9 47 47.0
Medication is not in the PFPB list 185 45.7 155 48.6 30 35.3
Other reasons 84 18.9 67 19.5 17 16.8
PFPB-E: Brazilian People’s Pharmacy Program – expansion model; SUS: Brazilian Unified Health System; PFPB: Brazilian People’s 
Pharmacy Program
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Table 3. Factors associated with use of the People’s Pharmacy Program in the last 15 days. Pelotas, RS, Southern Brazil, 2014.
Levela Variable p 95%CI PRcrude 95%CI p PRadjusted 95%CI p
b
1
Age < 0.001 0.004
60-64 60.6 34.0–44.7 1 - - 1 - -
65-69 59.1 53.5–64.7 0.97 86.3–1.10 - 0.97 0.85–1.11 -
70-79 60.5 55.7–65.3 0.99 87.7–1.14 - 1.02 0.89–1.16 -
≥ 80 41.1 34.4–47.9 0.67 56.3–81.9 - 0.72 0.60–0.87 -
Educational attainment (in years of schooling) 0.007 0.131
0 48.0 40.4–55.5 1 - - 1 - -
≤ 3 60.8 55.0–66.5 1.26 1.03–1.55 - 1.22 0.99–1.52 -
4-7 63.1 58.2–68.0 1.31 1.06–1.62 - 1.31 1.06–1.62 -
8-10 56.8 47.7–65.8 1.18 0.93–1.50 - 1.20 0.94–1.54 -
≥ 11 50.2 44.3–56.1 1.05 0.84–1.30 - 1.14 0.90–1.46 -
Income in minimum wages 0.001c 0.005c
≤ 1 56.9 47.7–66.0 1 - - 1 - -
2-3 61.5 57.2–65.8 1.08 0.90–1.30 - 1.0 0.83–1.20 -
4-5 60.0 53.8–66.2 1.05 0.86–1.30 - 0.97 0.77–1.22 -
6-9 50.6 43.0–58.1 0.88 68.7–1.15 - 0.83 0.63–1.10 -
≥ 10 40.9 32.4–49.4 0.72 0.55–0.94 - 0.66 0.49–0.90 -
Marital status 0.013 0.036
Living without a partner 52.6 48.5–56.6 1 - - 1 -
Living with a partner 60.8 57.0–64.6 1.16 1.03–1.30 - 1.13 1.0–1.28
2
Hypertension < 0.001 < 0.001
No 38.0 32.6–43.4 1 - - 1 -
Yes 63.2 60.0–66.3 1.66 1.41–1.96 - 1.52 1.29–1.77
Diabetes < 0.001 < 0.001
No 52.7 49.4–55.9 1 - - 1 -
Yes 68.1 63.0–73.1 1.30 1.19–1.40 - 1.19 1.09–1.30
Dyslipidemia < 0.001 < 0.001
No 48.1 44.3–51.8 1 - - 1 -
Yes 67.3 63.4–71.1 1.40 1.27–1.54 1.31 1.20–1.43
Glaucoma 0.128 0.129
No 56.2 53.4–59.1 1 1
Yes 63.9 54.2–73.6 1.14 0.96–1.34 1.13 0.96–1.34
Rhinitis 0.050 0.05
No 55.4 52.3–58.5 1 - - 1
Yes 62.1 56.0–68.2 1.12 1.0–1.25 - 1.12 0.99–1.26
3
Knowledge of the PFPB < 0.001 < 0.001
No 16.4 10.2–22.6 1 - - 1 - -
Yes 61.9 59.0–64.8 3.77 2.63–5.40 - 2.87 2.01–4.08 -
Number of medications used < 0.001c < 0.001c
1 37.5 28.7–46.3 1 - - 1 - -
2 41.1 34.0–48.1 1.09 80.3–1.49 - 0.96 71.6–1.28 -
3 53.5 46.9–60.0 1.42 1.06–1.90 - 1.22 92.0–1.62 -
≥ 4 65.6 62.0–69.1 1.74 1.35–2.26 - 1.40 1.07–1.80 -
PFPB: Brazilian People’s Pharmacy Program
a All variables were controlled for the others of the same level and above, with p from 0.2 to 0.05.
b The variables with significance level from 0.05 to 0.2 were maintained in the model to control confounding.
c Wald Test for linear trend.
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Among the 1,014 older adults who had not acquired all their medications from the 
PFPB-E or directly from SUS units, 54.0% had tried obtaining them from the program. 
The main reasons reported for not having obtained medication from the program were 
the medication not being in the PFPB-E list (74.0%), difficulty in getting the prescription 
(17.0%), and medication shortage (13.0%). Among those who did not try to get the 
medication from the PFPB-E, the main reasons were the medication not being in the 
PFPB-E list (46.0%), ignorance of which medications were available (39.0%) and no 
knowledge of the PFPB (29.0%) (Table 2).
Of the people aged 80 years or over who had not obtained all their medications from the 
PFPB-E or SUS, 42.0% had tried to get the medications from the program. This age group 
had more difficulty in obtaining the prescription (21.0%) and going to the pharmacy 
(12.0%) than the 60-79 years group (16.0% and 4.0%, respectively). About 45.0% of them 
reported lacking knowledge of the program and medications available as a reason not to 
try obtaining the medication from the PFPB-E. Among older people aged 80 years or over, 
16.0% reported difficulty in going to the pharmacy as a reason (Table 2).
Table 3 describes the factors associated with the use of the PFPB-E. The crude analysis 
showed no association with sex, skin color/race, occupation and social support. People 
aged 80 years or older presented a 28.0% lesser use of the PFPB-E than those aged 60-64 
years, while those living with partners used it 13.0% more than those without a partner. 
The use of the program decreased linearly with increasing income, and individuals with 
household income equal to or greater than 10 minimum wages used the program 34.0% 
less than those of lower income.
Individuals with chronic diseases as diabetes, hypertension, and dyslipidemia used the 
program 19.0%, 52.0%, and 31.0% more, respectively, than those without these morbidities. 
Older people who knew the PFPB used it three times more than those who did not, and 
individuals who took four or more medications used the PFPB-E 40.0% more than those 
who took only one medication (Table 3).
Table 4. Description of the medications in the PFPB-E list according to use of the program. Pelotas, RS, 
Southern Brazil, 2014. (N = 1,873)
Medication obtained from the PFPB-E n %
No 599 32.4
Yes 1,249 67.6
Medications obtained free of charge from the PFPB-E
No 258 20.7
Yes 991 79.3
Origin of the prescription of the medications obtained from the PFPB-E
SUS 569 45.6
Health plan or private 678 54.4
Description of the PFPB-E medications according to pharmacologic class
Respiratory diseases (asthma, bronchitis, emphysema) 31 1.7
Diabetes 351 18.7
Dyslipidemia 327 17.5
Glaucoma 15 0.8
Hypertension 1,092 58.3
Osteoporosis 34 1.8
Parkinson’s disease 13 0.7
Rhinitis 10 0.5
PFPB-E: Brazilian People’s Pharmacy Program – expansion model; SUS: Brazilian Unified Health System
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Of the 5,700 medications used by the older adults, 32.9% (n = 1,873) were part of the PFPB-E; 
of these, 67.6% (n = 1,249) were obtained from the program, of which 79.3% (n = 991) free of 
charge. As to the origin of the prescription used to obtain the medications from the people’s 
pharmacy, 54.4% were from private or health plan professionals. The most used medications 
by the PFPB-E, according to pharmacological classification, were antihypertensive drugs 
(58.3%), antidiabetic drugs (18.7%), and lipid modifying agents (17.5%) (Table 4).
Among the medications used for chronic conditions such as respiratory diseases, diabetes, 
and hypertension, 41.9%, 85.2%, and 58.9%, respectively, were present in the PFPB-E list 
(data not shown in tables).
The design effect of this study was 1.14, the intra-class correlation coefficient was 0.0099, and 
the kappa index of the variable “PFPB knowledge” presented good reproducibility (kappa ≥ 0.7).
DISCUSSION
Of the older people who used medications, more than 80.0% knew the PFPB and more than 
half used it. However, those aged 80 years or over used the program less. This shows that 
the program is very disseminated, except among the oldest adults. In addition, a significant 
portion of the older adults with prescriptions from SUS obtained medications from the 
PFPB-E, even though they are not its priority group. 
In a 2008 population-based study in adults aged 20 years or over, knowledge of the PFPB 
was 32.8%8. The greater knowledge of PFPB in this study may result from the increased time 
between data collection and the beginning of the program or from the exclusive participation 
of older adults, who use medications and health services more, increasing the opportunities 
to learn about the program8,10.
The main barriers to the use of the program are lack of prescription, medication shortage, 
and the medication not being part of the program, suggesting difficulty of access to medical 
appointments and insufficient programming of medication supply and distribution. Although 
the number of medications offered by the program is great (including the vast majority of 
treatments for chronic conditions) and the list is revised periodically, it is necessary to assess 
whether the medications included in the program satisfy properly the treatment needs of 
the population9. On the other hand, the program includes medications similar to others that 
are not part of the program, indicating that physicians possibly fail to prioritize or to know 
the medications in the program1,16. 
We also noted that difficulty in going to the pharmacy is a major problem for people aged 80 
years or over since, in the absence of the patient, a legal representative is required to collect 
the medication. Although the existence of the program is widely known, there is still a lack 
of information, especially among people aged 80 years or over. The list of medications offered 
by the program is the least known aspect by the population. 
Use of the PFPB-E was greater in the older adults aged less than 80 years. The reduction in 
the use of the program by people aged 80 years or over might reflect inequality in access to 
medications since as age increases, older adult tends to be more medicalized. This inequality 
might be related to inability or difficulty of mobility, which hinders access to medical 
appointments to renew the prescription and going to the registry to obtain the power of 
attorney required in case of a legal representative collecting the medication. 
The study was consistent with the findings of Costa et al.8, who found no association between 
sex of respondents and use of the program. Women live longer, seek health services more2 
and use more medications2,10,18. Thus, no association can be observed for the concentration 
of women in the 80 years or over group, which faces barriers to access the program. 
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Individuals with partners used the PFPB-E more, which is consistent with the fact that 
individuals with partners use health services more7,8. Consequently, these individuals are 
more likely to diagnose diseases, to have access to prescriptions and to receive information 
regarding the PFPB.
This study shows, consistently with the literature, that the program serves all socioeconomic 
strata of the population8,15. In addition, although most prescriptions used by the elderly to 
obtain the medications were from the private sector, the number of users of the public network 
is high, accounting for 46.0%, in accordance with what Pinto et al.14,15 found in their research.
A 2007 case study including municipalities from the five regions of Brazil suggests that 
users may have sought the program because of the ready availability of medications 
and its shorter wait. Centralizing medication purchasing can reduce pharmaceutical 
assistance costs, but the fact that medications for asthma, diabetes, and hypertension 
are available free of charge in the PFPB does not exempt state and municipal managers 
from the continuity of their provision. They should be available in primary health care 
pharmacies, facilitating the access for SUS usersm. Thus, failures in the free-of-charge 
provision of medications by municipal public networks overloads the demand of the 
PFPB-E, creating costs for the user, both with medications not covered by the program 
and with transportation to the pharmacy. 
Medication shortage in the public and private sectors (PFPB-E) implies a greater part of 
users’ income destined to health expenditure, which is already extremely high. The situation 
is even more complicated for those who fail to adhere to the treatment for the lack of money 
to purchase medication, which often worsens their health status4. 
In accordance with previous studies6,11,15,17, the most used PFPB medications were those for 
cardiovascular conditions and those related to metabolism. That can be partly explained by 
the fact that these medications are available free of charge and by their consumption pattern, 
which reflects the profile of the chronic diseases most prevalent among older adults5,12.
The studied sample is representative of the older population residing in urban areas. 
Losses were not substantially different from the studied population, which reinforces the 
internal validity. As this study addressed only the PFPB private networks, its results can 
be generalized to municipalities with these characteristics. To better qualify the outcome 
characterization, we requested the packaging or prescription of all medications listed by 
the respondents. The lack of other household surveys concerning the PFPB-E limited the 
consistency analysis of this study. 
The results obtained by this population survey expand knowledge regarding the use of the 
PFPB-E by the older population and of the reasons for not using it. Thus, they contribute 
to defining policies to qualify the program. People aged 80 years or over present a great 
need for access to medications and, according to the Brazilian Institute of Geography and 
Statistics (IBGE), the number of people in this age group increased by 70.0% from 2000 
to 2010n. This situation requires measures to reduce the inequality in the pharmaceutical 
assistance to this age group as well as to expand the use of the program. Expanding home 
care can contribute to this end, facilitating the obtaining of the prescription. However, 
considering the mobility difficulties characteristic of this population group, it is critical 
to study alternatives to the requirement of power of attorney for legal representatives to 
receive medication from the pharmacy. 
Disseminating the list of medications offered by the program both for the population and for 
physicians is necessary. This knowledge can contribute to increasing the use of the program 
by older adults and to health professionals, whenever possible, directing the prescription to 
medications in the list, reducing expenditure on long-term medications, which are especially 
important for this population1,9. 
m Ministério da Saúde. 
Crescimento do Programa 
Farmácia Popular. Brasília (DF); 
2013 [cited 2014 Mar]. Available 
from: http://www.cosemsms.org.
br/ultimas-noticias/farmacia-
popular-nota-de-esclarecimento
n Instituto Brasileiro de Geografia 
e Estatística. Censo demográfico 
e contagem da população. Rio 
de Janeiro (RJ); 2014. Available 
from: http://www.sidra.ibge.gov.
br/bda/tabela
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The PFPB added an enormous cost to pharmaceutical assistance with the currently available 
medications and the gratuitousness of the most used medications for asthma, diabetes and 
hypertension. A PFPB medication can cost up to 290.0% more for the Brazilian Ministry of 
Health than for the Farmácia Básica (Primary Pharmacy)o.
It is crucial that local authorities take responsibility for the pharmaceutical assistance of 
SUS users, promoting access to medication and the effective insertion of pharmaceutical 
assistance as a health action, especially for those in remote areas, with a medication 
supply closer to the user. This strategy is crucial to avoid spending on medications and 
transportation, and even low adherence to treatment in the low-income population.
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